Clinical ink's BrainBaseline Technology Assists in Revolutionary Cannabis Research
The recently published JAMA Psychiatry paper, Driving Performance and Cannabis Users’ Perception of Safety: A Randomized Clinical Trial, suggests a path forward to quantifying the effects of cannabis. In this cannabis research trial, the team deployed our digitized, cognitive and behavioral assessments – available on Clinical ink’s BrainBaseline™ platform – to help measure cannabis-related impairment.
- Patients self-administered our BrainBaseline™ assessments both in and outside a driving simulator, resulting in “driving decrements” with cannabis use.
- Users’ driving decrements were not able to be correlated with the amount of cannabis ingested or THC blood concentration. As a result, the study reinforces the need for different methods to measure the effects of cannabis use, as well as the potential of a digital, self-administered cognitive battery like ours.
Learn more in our press release on this groundbreaking cannabis research.
See everything our clinical data platform has to offer